Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11046-023-00719-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Novel Technique to Extract Implanted Leads Using Simple Stylets and Reused Rotational Sheaths in Patients with a Cardiac Implantable Electronic Device.
Turk Kardiyol Dern Ars
September 2025
Division of Arrhythmia and Electrophysiology, Department of Cardiology, University of Health Sciences, Yuksek Ihtisas Cardiovascular Building, Ankara City Hospital, Ankara, Türkiye.
Objective: Transvenous lead extraction (TLE) is used in various clinical scenarios, such as device-related infections. Mechanically powered sheaths are one of the most commonly used tools for TLE procedures. We evaluated the procedural and clinical outcomes of a novel extraction technique for chronically implanted leads in the treatment of device-related infections.
View Article and Find Full Text PDFA case of successful pembrolizumab plus FP neoadjuvant chemotherapy for a tumor preoperatively diagnosed as gastric squamous cell carcinoma.
Clin J Gastroenterol
September 2025
Department of Gastroenterology, Akita University Graduate School of Medicine, Hondo 1-1-1, Akita City, Akita, Japan.
Primary gastric squamous cell carcinoma (GSCC) or gastric adenosquamous carcinoma (GASC) is an uncommon histologic type for which no standard treatment has been established. The prognosis is poor, and there are few reports of effective treatment. Here, we experienced a case of GASC that was diagnosed preoperatively as GSCC and could be operated on after successful preoperative chemotherapy with pembrolizumab, 5-fluorouracil, and cisplatin.
View Article and Find Full Text PDFNanotechnology for CAR T cells and tumour-infiltrating lymphocyte therapies.
Nat Nanotechnol
September 2025
John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA.
Adoptive T-cell therapies, and particularly CAR T cells and tumour-infiltrating lymphocytes, have transformed cancer treatment by selectively targeting malignant cells. Despite their clinical success, these therapies face substantial challenges, including costly manufacturing processes and tumour-imposed barriers that limit efficacy. Advances in understanding the nanoscale mechanisms governing T-cell activation and the role of the tumour microenvironment in restricting T-cell responses have driven the development of nanotechnology-based strategies that integrate key chemical and physical cues.
View Article and Find Full Text PDFEnhancing bonding and durability of polyaryletherketone (PAEK) restorations with nonthermal plasma activation and monomer-based priming.
J Prosthet Dent
September 2025
Associate Professor, School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan, ROC. Electronic address:
Statement Of Problem: While valued for their durability in dental prosthetics, polyaryletherketone (PAEK) materials, known for their chemical inertness and low surface energy, pose significant challenges in achieving durable adhesion to resin cements, a critical factor for the long-term success of dental restorations.
Purpose: This study evaluates the novel application of a methyl methacrylate-urethane dimethacrylate (MMA-UDMA) bonding primer following handheld nonthermal plasma (HNP) treatment to enhance the bonding performance and aging durability of PAEK materials with varying microfiller compositions, addressing the persistent challenge of achieving long-term adhesion in dental restorations.
Material And Methods: Three PAEK types, ceramic-filled polyetheretherketone (PEEK), titanium dioxide-filled polyetherketoneketone (PEKK), and PEEK with disk shape (Ø10×2.
Agranulocytosis Following Durvalumab Plus Tremelimumab Therapy for Hepatocellular Carcinoma: A Case Report.
Intern Med
September 2025
Department of Gastroenterology and Hepatology, Toyota Kosei Hospital, Japan.
Agranulocytosis is an extremely rare but potentially fatal immune-related adverse event (irAE) induced by immune checkpoint inhibitors (ICIs). Its management, particularly following combination therapies such as durvalumab/tremelimumab (Dur/Tre) for hepatocellular carcinoma (HCC), is challenging owing to limited data. We herein report a 79-year-old man with HCC who developed severe Dur/Tre-induced agranulocytosis that was refractory to granulocyte colony-stimulating factor, high-dose corticosteroids, and intravenous immunoglobulin.
View Article and Find Full Text PDF